US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altech Digitial Co.

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:- -

Open:- -

Low:- -

Close:- -

52wk High:- -

52wk Low:- -

Shares:29.50M

Float Shares:1.50M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:259.58%

ROA:48.64%

PB:0.00

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Ampol (ASX:ALD) Takes On Some Risk With Its Use Of Debt

Simply Wall St.

1 Super Semiconductor Stock (Besides Nvidia or Broadcom) to Buy Hand Over Fist

Press Release: Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Altimmune to Participate in Two Upcoming Investor Conferences

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ALD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","market":"US","secType":"STK","nameCN":"Altech Digitial Co.","latestPrice":0,"timestamp":1760731200000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":1500000,"shares":29500000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"10-17 16:00:00 EDT","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1760500800000,"exchange":"NASDAQ","adjPreClose":0,"sharesOutstanding":400000,"nav":44.492139,"aum":17756473.36,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","floatShares":1500000,"roa":"48.64%","roe":"259.58%","lyrEps":0,"shares":29500000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575976839","title":"Ampol (ASX:ALD) Takes On Some Risk With Its Use Of Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2575976839","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575976839?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:00","pubTimestamp":1760558404,"startTime":"0","endTime":"0","summary":"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-asxald-takes-on-some-risk-with-its-use-of-debt-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-asxald-takes-on-some-risk-with-its-use-of-debt-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7065","EBIT","ALD.AU","ALD"],"gpt_icon":0},{"id":"2572532164","title":"1 Super Semiconductor Stock (Besides Nvidia or Broadcom) to Buy Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2572532164","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572532164?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:45","pubTimestamp":1759326300,"startTime":"0","endTime":"0","summary":"Investors should start looking beyond prominent names in the AI infrastructure space.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835396%2Fanalyst_analyzing_stock_charts_on_desktop_and_laptop.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835396%2Fanalyst_analyzing_stock_charts_on_desktop_and_laptop.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/01/1-semiconductor-stock-besides-nvidia-or-broadcom/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/01/1-semiconductor-stock-besides-nvidia-or-broadcom/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1066051498.USD","IE00BQXX3F31.USD","SNVD.UK","NVD","NVDD","LU2290526834.HKD","2NVD.UK","LRCX","LU1852331112.SGD","NVD3.UK","3NVD.UK","AVGOP","HK0000306685.HKD","SAM","LU0276348264.USD","LU1037948897.HKD","LU2063271972.USD","NVIW.SI","NVDX","LU2108987350.USD","LU1242518931.SGD","LU1861127337.USD","LU1935043536.SGD","IE00BQXX3C00.GBP","NVD2.UK","SOXX","LU0265550359.USD","LU0345768153.USD","NVDS.UK","LU1989772923.USD","GAA","LU0557290698.USD","NVDU","NVDS","NVDY","ALD","SMH","LU1923622291.USD","LU2244417387.USD","LU0127658192.USD","LU2433249047.HKD","LU2213496289.HKD","LU1989772840.SGD","LU1815336760.USD"],"gpt_icon":1},{"id":"2571380575","title":"Press Release: Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide","url":"https://stock-news.laohu8.com/highlight/detail?id=2571380575","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571380575?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:30","pubTimestamp":1759145400,"startTime":"0","endTime":"0","summary":"Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH. Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises. \"We are thrilled to welcome Christophe to the team at this crucial juncture in Altimmune's evolution,\" said Vipin K. Garg, Ph.D., President and CEO of Altimmune. \"He brings a wealth of experience across mid- and late-stage clinical development, regulatory approvals and commercial launches that will be invaluable as we continue to advance pemvidutide and work toward our mission of establishing a new standard of care in the treatment of hepato-metabolic disorders. On behalf of the executive team and Board of Directors, I would also like to thank Scott for his instrumental contributions over the last six years. His oversight of the pemvidutide program through multiple INDs and clinical trials has positioned us well as we prepare to enter Phase 3 development in MASH.\". Dr. Arbet-Enge","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4232","BK4139","LU1878469433.USD","BK4599","BK4022","R","ALD"],"gpt_icon":0},{"id":"2569797843","title":"Altimmune to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2569797843","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569797843?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:30","pubTimestamp":1758627000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Sept.  23, 2025  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/23/3154577/0/en/Altimmune-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALD\",params:#limit:6,delay:false,,,undefined,":[]}}